B Johansson1, A-P Wentzel, P Andréll, C Mannheimer, L Rönnbäck. 1. Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg , Gothenburg , Sweden .
Abstract
OBJECTIVE: Post-traumatic brain injury symptoms, such as mental fatigue, have considerable negative impacts on quality-of-life. In the present study the effects of methylphenidate in two different dosages were assessed with regard to mental fatigue, pain and cognitive functions in persons who had suffered a traumatic brain injury. METHODS:Fifty-one subjects were included and 44 completed the study. The treatment continued for 12 weeks, including three treatment periods with no medication for 4 weeks, administration of low dose methylphenidate (up to 5 mg × 3) for 4 weeks and normal dose methylphenidate (up to 20 mg × 3) for a further 4 weeks. The patients were randomized into three groups where all groups were given all treatments. RESULTS: Significantly reduced mental fatigue, assessed with the Mental Fatigue Scale (MFS) andincreased information processing speed (coding, WAIS-III), were detected. The SF-36 vitality and social functioning scales were also improved significantly. Pain was not reduced by methylphenidate. The positive effects of treatment were dose-dependent, with the most prominent effects being at 60 mg methylphenidate/day spread over three doses. Observed side-effects were increased blood pressure and increased heart rate. CONCLUSIONS:Methylphenidate was generally well-tolerated and it improved long-lasting mental fatigue and processing speed after traumatic brain injury.
RCT Entities:
OBJECTIVE: Post-traumatic brain injury symptoms, such as mental fatigue, have considerable negative impacts on quality-of-life. In the present study the effects of methylphenidate in two different dosages were assessed with regard to mental fatigue, pain and cognitive functions in persons who had suffered a traumatic brain injury. METHODS: Fifty-one subjects were included and 44 completed the study. The treatment continued for 12 weeks, including three treatment periods with no medication for 4 weeks, administration of low dose methylphenidate (up to 5 mg × 3) for 4 weeks and normal dose methylphenidate (up to 20 mg × 3) for a further 4 weeks. The patients were randomized into three groups where all groups were given all treatments. RESULTS: Significantly reduced mental fatigue, assessed with the Mental Fatigue Scale (MFS) and increased information processing speed (coding, WAIS-III), were detected. The SF-36 vitality and social functioning scales were also improved significantly. Pain was not reduced by methylphenidate. The positive effects of treatment were dose-dependent, with the most prominent effects being at 60 mg methylphenidate/day spread over three doses. Observed side-effects were increased blood pressure and increased heart rate. CONCLUSIONS:Methylphenidate was generally well-tolerated and it improved long-lasting mental fatigue and processing speed after traumatic brain injury.
Authors: Julie K Silver; Vishwa S Raj; Jack B Fu; Eric M Wisotzky; Sean Robinson Smith; Rebecca A Kirch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi Journal: Prog Neurobiol Date: 2016-05-07 Impact factor: 11.685
Authors: Brenna C McDonald; Laura A Flashman; David B Arciniegas; Robert J Ferguson; Li Xing; Jaroslaw Harezlak; Gwen C Sprehn; Flora M Hammond; Arthur C Maerlender; Carrie L Kruck; Karen L Gillock; Kim Frey; Rachel N Wall; Andrew J Saykin; Thomas W McAllister Journal: Neuropsychopharmacology Date: 2016-11-22 Impact factor: 7.853
Authors: Marilyn Huckans; Stephen Boyd; Grant Moncrief; Nathan Hantke; Bethany Winters; Kate Shirley; Emily Sano; Holly McCready; Laura Dennis; Milky Kohno; William Hoffman; Jennifer M Loftis Journal: J Clin Exp Neuropsychol Date: 2021-10-06 Impact factor: 2.283
Authors: Jacob B Leary; Corina O Bondi; Megan J LaPorte; Lauren J Carlson; Hannah L Radabaugh; Jeffrey P Cheng; Anthony E Kline Journal: J Neurotrauma Date: 2016-05-09 Impact factor: 5.269
Authors: Antonio Verduzco-Mendoza; Paul Carrillo-Mora; Alberto Avila-Luna; Arturo Gálvez-Rosas; Adriana Olmos-Hernández; Daniel Mota-Rojas; Antonio Bueno-Nava Journal: Front Neurosci Date: 2021-06-24 Impact factor: 4.677